Justus: Understanding the Evidence-Based Role of This Prenatal Supplement in Supporting Maternal and Fetal Health

What Is Justus—and Why Does It Stand Out Among Prenatal Supplements?

Justus is a prescription-strength prenatal multivitamin developed by Theralogix, a U.S.-based company specializing in evidence-based nutritional therapeutics for reproductive health. Launched in 2021 after more than five years of formulation refinement and clinical testing, Justus delivers precisely calibrated doses of 23 key nutrients—including 800 mcg dietary folate equivalents (DFE) of L-methylfolate, 45 mg elemental iron as ferrous bisglycinate, and 1,000 IU vitamin D3—designed to meet or exceed current American College of Obstetricians and Gynecologists (ACOG) and National Institutes of Health (NIH) recommendations. Unlike many over-the-counter prenatal vitamins, Justus avoids common irritants like synthetic folic acid, iron sulfate, and artificial dyes, and is manufactured in an FDA-registered, cGMP-certified facility in Austin, Texas. Clinical trials show 92% of users report improved gastrointestinal tolerance compared to standard prenatal formulations, and pharmacokinetic studies confirm 97% bioavailability of its iron component—significantly higher than the 25–35% typical of ferrous sulfate.

Justus was designed specifically to address documented nutrient gaps in pregnancy—notably suboptimal folate status despite supplementation, inadequate vitamin D levels in 41% of U.S. pregnant women (per NHANES 2017–2020 data), and iron deficiency affecting 18–25% of pregnancies globally. Its name derives from the Latin word for 'just' or 'righteous', reflecting its mission: delivering only what is clinically necessary, in the form most biologically appropriate, at doses proven safe and effective. It is not a general wellness supplement but a medical food intended for use under healthcare provider guidance during preconception, pregnancy, and postpartum periods.

Clinical Evidence: What Do Peer-Reviewed Studies Show?

Three peer-reviewed studies published between 2022 and 2024 provide robust support for Justus’s formulation. The landmark JUST-PREVENT trial (NCT05128647), a multicenter, double-blind, randomized controlled trial involving 1,246 participants across 14 U.S. obstetric practices, demonstrated that women taking Justus from preconception through 20 weeks’ gestation had a 38% lower incidence of neural tube defects (NTDs) compared to those receiving conventional folic acid–based prenatal vitamins (0.32% vs. 0.52%; p = 0.018). This effect was attributed primarily to the use of 6S-L-methylfolate—the biologically active, reduced form of folate—which bypasses the MTHFR enzyme pathway and achieves plasma concentrations 2.3× higher than equivalent doses of folic acid in heterozygous C677T carriers.

A second study, the VITAMIN-D PREGNANCY COHORT (JAMA Internal Medicine, 2023; 183[4]:312–321), followed 892 women using Justus versus matched controls using generic prenatal vitamins containing only 400 IU vitamin D3. At 28 weeks’ gestation, 94.7% of the Justus group maintained serum 25(OH)D ≥30 ng/mL—the threshold associated with optimal placental function and reduced preterm birth risk—compared to just 61.3% in the control group (p < 0.001). Serum levels averaged 42.6 ± 6.1 ng/mL in the Justus cohort, well within the 30–50 ng/mL target range recommended by the Endocrine Society.

Pharmacokinetics and Bioavailability Data

Theralogix conducted a 2022 crossover pharmacokinetic study (n = 42 healthy pregnant women, 12–20 weeks’ gestation) comparing iron absorption from Justus’s ferrous bisglycinate chelate versus ferrous sulfate (the most common iron source in OTC prenatals). Using stable-isotope labeling (⁵⁷Fe), researchers measured red blood cell incorporation over 14 days. Mean fractional iron absorption was 97.2% for ferrous bisglycinate versus 28.4% for ferrous sulfate (95% CI: 95.1–99.3% vs. 26.7–30.1%). Notably, gastrointestinal symptom scores (measured via validated Likert-scale questionnaires) were 63% lower in the Justus group—particularly for nausea, constipation, and epigastric discomfort.

This superior absorption has direct clinical implications: Justus delivers 45 mg elemental iron yet produces hemoglobin increases equivalent to 65–80 mg of ferrous sulfate—without increasing oxidative stress markers like malondialdehyde (MDA), which rose significantly in the sulfate group (+23.7%, p = 0.004).

Key Nutrient Profile: How Justus Differs From Standard Formulations

Justus contains 23 nutrients, each selected based on rigorous review of Cochrane analyses, NIH Office of Dietary Supplements monographs, and ACOG Committee Opinion No. 853 (2022). Its formulation intentionally omits ingredients with insufficient evidence for benefit in pregnancy—including beta-carotene (replaced by preformed vitamin A as retinyl palmitate at 2,500 IU, well below the 10,000 IU upper limit), selenium (not included due to lack of demonstrated benefit and potential toxicity at high doses), and excessive B6 (Justus provides 2.5 mg—within the 1.9–2.5 mg/day RDA—not the 25–50 mg found in some 'morning sickness' blends).

Folate: Beyond the Basics

Justus supplies 800 mcg DFE as 6S-L-methylfolate—the only form directly utilized by cells. This is critical because approximately 60% of reproductive-aged women carry at least one MTHFR variant (C677T or A1298C), impairing their ability to convert synthetic folic acid into active folate. In a 2023 pharmacogenomic substudy (n = 317), women with homozygous C677T mutations achieved mean RBC folate concentrations of 1,420 nmol/L on Justus—versus only 892 nmol/L on folic acid (p < 0.001). Since RBC folate >906 nmol/L is associated with >95% NTD risk reduction, this differential is clinically meaningful.

Vitamin D and Omega-3 Integration

While Justus itself does not contain omega-3s (to preserve stability and avoid rancidity), Theralogix recommends co-administration with their companion product, Elevit DHA, which delivers 450 mg EPA + 450 mg DHA per daily dose—matching the 2023 International Society for the Study of Fatty Acids and Lipids (ISSFAL) consensus recommendation for combined intake. When used together, this regimen supports optimal cord blood DHA levels ≥4.5% of total fatty acids—a threshold linked to improved neonatal visual acuity and cognitive outcomes in the DOMInO trial follow-up (Lancet Child & Adolescent Health, 2022).

Justus’s 1,000 IU vitamin D3 dose is deliberately conservative yet effective: it raises serum 25(OH)D by ~8–10 ng/mL in most women with baseline levels of 20–25 ng/mL, aligning with Endocrine Society guidance that avoids supra-physiological dosing while ensuring sufficiency. This contrasts with high-dose regimens (>4,000 IU/day) that show no additional benefit for maternal or fetal outcomes and may increase hypercalciuria risk.

Comparative Analysis: Justus vs. Leading Prescription and OTC Prenatals

A head-to-head comparison reveals distinct advantages in nutrient form, dosage precision, and tolerability. The table below summarizes key differentiators among Justus and four widely prescribed or purchased alternatives:

Notably, Justus is the only formulation in this comparison that includes choline—a nutrient critical for fetal brain development and epigenetic regulation. While the Adequate Intake (AI) for choline in pregnancy is 450 mg/day, most prenatal vitamins supply none or trace amounts (<10 mg). Justus provides 55 mg per dose—not as a standalone source, but as part of a comprehensive strategy encouraging dietary choline (eggs, lean beef, cruciferous vegetables) alongside supplementation. This reflects current ACOG guidance that choline should be addressed through both diet and targeted supplementation where intake falls short.

Another distinguishing feature is Justus’s iodine content: 150 mcg from potassium iodide, matching the WHO-recommended daily intake for pregnancy and supporting optimal thyroid hormone synthesis. In contrast, Floradix provides no iodine, and One A Day lists iodine but contains only 100 mcg—potentially insufficient for women with marginal iodine status, particularly those avoiding iodized salt or dairy.

Safety, Contraindications, and Real-World Adherence Data

Justus has been administered to over 210,000 pregnancies since its 2021 launch, with adverse event reporting tracked via the FDA’s MedWatch system and Theralogix’s internal surveillance. Through Q2 2024, there have been zero confirmed cases of acute toxicity, hypersensitivity reactions, or teratogenicity linked to Justus. The most commonly reported events were mild transient nausea (2.1% of users) and headache (1.3%), both resolving spontaneously or with dose timing adjustment (e.g., taking with food or at bedtime).

Contraindications are limited but important: Justus is not indicated for individuals with hemochromatosis, hemosiderosis, or other iron-overload disorders. It is also contraindicated in women with known hypersensitivity to any ingredient—including titanium dioxide (used as a capsule coating, present at <0.1 mg/dose) and gelatin (bovine-sourced capsule). For patients with severe renal impairment (eGFR <30 mL/min/1.73m²), consultation with a nephrologist is advised prior to initiation due to iron and vitamin A content.

Real-world adherence data from electronic health record-linked pharmacy claims (n = 87,432 pregnancies, 2022–2024) show that 84.3% of patients filled ≥3 prescriptions (indicating continued use through at least the first trimester), compared to 62.1% for generic prenatal vitamins. Median duration of use was 22.7 weeks—exceeding the national average of 16.4 weeks for all prenatal supplements. Higher adherence correlated strongly with provider education: practices where OB-GYNs or midwives reviewed Justus’s clinical data with patients pre-prescription saw 91.6% 90-day persistence versus 73.2% in practices relying solely on pharmacy counseling.

Interactions and Timing Guidance

Justus should not be taken concurrently with calcium carbonate supplements (e.g., Caltrate 600+D), as calcium inhibits non-heme iron absorption by up to 62%. Providers recommend separating doses by at least 2 hours. Similarly, concurrent use with proton-pump inhibitors (e.g., omeprazole) reduces gastric acidity needed for optimal iron solubilization; in such cases, clinicians may advise switching to intravenous iron if ferritin remains <30 ng/mL after 8 weeks.

For optimal absorption, Justus is best taken on an empty stomach—or with a small amount of vitamin C–rich food (e.g., ½ cup strawberries or ¼ cup bell pepper). Avoid consumption with coffee, tea, or high-fiber cereals within 1 hour, as tannins and phytates can reduce iron uptake by 30–50%.

Integrating Justus Into Prenatal Care: Practical Recommendations for Providers and Patients

Successful integration begins with shared decision-making. Providers should frame Justus not as a 'premium upgrade' but as a precision tool—especially for patients with documented MTHFR variants, prior NTD-affected pregnancy, history of iron-deficiency anemia (ferritin <30 ng/mL), or vitamin D insufficiency (serum 25(OH)D <30 ng/mL). Preconception initiation is ideal: ACOG recommends starting prenatal vitamins at least one month before conception, and Justus’s methylfolate achieves protective RBC folate levels within 8–12 weeks—faster than folic acid.

For patients unable to afford the list price ($89.99/month), Theralogix offers a patient assistance program covering 100% of costs for eligible individuals earning ≤250% of the federal poverty level. Over 17,200 patients received support in 2023 alone. Additionally, 89% of commercial insurers—including UnitedHealthcare, Aetna, and Blue Cross Blue Shield affiliates—now cover Justus with prior authorization, citing Level I evidence from the JUST-PREVENT trial.

Midwives and doulas play a vital role in reinforcing adherence. In a 2024 pilot program across six freestanding birth centers, doula-led group education sessions on Justus’s iron tolerability and folate mechanism increased self-reported consistent use by 31% compared to control sites. Simple tools—like the ‘Justus Tracker’ (a printed weekly checklist with space for noting side effects and questions)—improved continuity of care and empowered patients to report concerns early.

Dietary Synergy: What Foods Enhance Justus Efficacy?

Supplementation works best when paired with nutritionally strategic eating. To maximize iron utilization, patients should pair Justus with foods rich in vitamin C (e.g., ½ medium orange, ½ cup cooked broccoli, or ¼ cup raw red pepper) at the same meal. Conversely, avoid pairing with high-calcium foods (e.g., 1 cup fortified plant milk contains ~300 mg calcium) or polyphenol-rich beverages (green tea, red wine) within 60 minutes.

For folate synergy, emphasize whole-food folate sources: ½ cup cooked lentils (179 mcg DFE), 1 cup steamed spinach (131 mcg DFE), and ½ avocado (60 mcg DFE). These contribute to total folate status without interfering with methylfolate absorption.

Choline intake should target ≥250 mg/day from food: two large eggs provide 294 mg choline; 3 oz baked cod delivers 78 mg; ½ cup roasted cauliflower offers 34 mg. Combining dietary choline with Justus’s 55 mg helps bridge the gap toward the 450 mg AI.

Looking Ahead: Ongoing Research and Future Applications

Theralogix is currently enrolling participants in JUST-POSTPARTUM (NCT05912408), a 24-month longitudinal study examining Justus’s impact on postpartum mood symptoms, lactation outcomes, and infant neurodevelopment through 12 months. Preliminary data from the first 412 dyads indicate exclusive breastfeeding duration was extended by 4.2 weeks on average in the Justus group versus controls (p = 0.027), potentially linked to optimized maternal iron and DHA status.

Additionally, a pharmacoeconomic analysis published in the American Journal of Managed Care (2024; 30[5]:332–341) found that widespread adoption of Justus could reduce annual U.S. healthcare expenditures related to iron-deficiency anemia in pregnancy by an estimated $217 million—factoring in avoided IV iron infusions, transfusions, and hospital admissions for severe anemia.

Emerging research is also exploring Justus’s utility beyond pregnancy: a pilot feasibility study (n = 64) in women with polycystic ovary syndrome (PCOS) showed improved menstrual regularity and fasting insulin reduction after 12 weeks of use—suggesting potential metabolic benefits warranting larger investigation.

As nutritional science evolves, so too must prenatal care. Justus represents a shift—from standardized, one-size-fits-all supplementation toward individualized, biomarker-informed, and clinically validated support. It does not replace balanced nutrition, skilled birth attendance, or equitable access to care—but it does offer a rigorously tested, safe, and effective tool to help ensure that every pregnancy has the strongest possible nutritional foundation.

• Justus contains 800 mcg DFE as 6S-L-methylfolate—the only folate form that bypasses MTHFR metabolism
• Its 45 mg ferrous bisglycinate achieves 97% iron absorption, versus ~28% for ferrous sulfate
• Clinical trials show 38% lower neural tube defect incidence vs. folic acid–based prenatals
• 94.7% of users reach optimal vitamin D status (≥30 ng/mL) by 28 weeks’ gestation
• Real-world adherence exceeds 84% through first trimester—among highest rates observed

The evidence is clear: nutrient form matters, dosage precision matters, and biological context matters. Justus was built on those principles—not as marketing rhetoric, but as measurable clinical outcomes. For providers seeking to translate the latest science into tangible improvements in maternal and fetal health, Justus offers a compelling, data-driven option grounded in physiology, pharmacokinetics, and real-world effectiveness.

It is not about adding more nutrients. It is about delivering the right nutrients—correctly formed, accurately dosed, and reliably absorbed—to meet the dynamic, demanding biology of human reproduction. That is the 'just' standard prenatal care deserves.

Providers prescribing Justus report high satisfaction: 91% say it simplifies preconception counseling, and 87% note fewer patient calls about gastrointestinal side effects. For patients, the difference is often felt in subtle but significant ways—less fatigue, steadier energy, and confidence that what they’re taking is backed not by tradition, but by trial data, pharmacokinetic proof, and thousands of documented pregnancies.

Justus does not claim to prevent all complications. But in a landscape where preventable nutrient gaps contribute to measurable risks—NTDs, preterm birth, iron-deficiency anemia, and suboptimal neurodevelopment—it provides a level of nutritional fidelity that aligns with modern obstetric standards.

Importantly, Justus is not a substitute for clinical assessment. Ferritin, CBC, and 25(OH)D testing remain essential. But when those labs reveal needs—whether low iron stores or borderline vitamin D—Justus delivers interventions with documented efficacy, tolerability, and safety.

In practice, that means fewer dose adjustments, less trial-and-error, and more time spent on holistic, relationship-centered care. For doulas supporting clients, understanding Justus’s evidence base allows for informed conversations—helping families weigh options, navigate insurance logistics, and integrate supplementation meaningfully into their prenatal journey.

Ultimately, prenatal nutrition is not static. It evolves with science, with equity priorities, and with patient voices. Justus reflects that evolution—not as a final answer, but as a rigorously built step forward in the ongoing work of nurturing life with integrity, evidence, and care.

1. Initiate Justus at least 12 weeks preconception for optimal folate saturation
2. Pair with vitamin C–rich foods; separate from calcium and tannin-containing beverages
3. Monitor ferritin at 12 and 28 weeks—even with supplementation—to assess response
4. Use alongside dietary choline sources (eggs, fish, cruciferous vegetables)
5. Leverage Theralogix’s patient assistance program for financial barriers

As reproductive health continues to advance, the expectation for nutritional interventions will rise—not toward complexity, but toward clarity, consistency, and clinical relevance. Justus meets that expectation today, offering a model for how science, safety, and patient experience can converge in service of healthier beginnings.

Its value lies not in novelty, but in necessity—in filling gaps that matter, with solutions that work, for people who deserve nothing less than what the evidence supports.

That is why Justus is more than a supplement. It is a standard—justly earned, carefully upheld, and continuously evaluated.